Publication:
The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients

Simple item page
dc.contributor.authorAĞAN YILDIRIM, KADRİYE
dc.contributor.authorsGunal, D. Ince; Agan, K.; Afsar, N.; Borucu, D.; Us, O.
dc.date.accessioned2022-03-12T17:33:32Z
dc.date.available2022-03-12T17:33:32Z
dc.date.issued2008
dc.description.abstractObjectives: Autosomal dominant cerebellar ataxias are clinically and genetically heterogeneous neurodegenerative disorders. There is no known treatment to prevent neuronal cell death in these disorders. Current treatment is purely symptomatic; ataxia is one of the most disabling symptoms and represents the main therapeutic challenge. A previous case report suggesting benefit from administration of high dose piracetam inspired the present study of the efficacy of this agent in patients with cerebellar ataxia. Piracetam is a low molecular weight derivative of gamma-aminobutyric acid. Although little is known of its mode of action, its efficacy has been documented in a wide range of clinical indications, such as cognitive disorders, dementia, vertigo and dyslexia, as well as cortical myoclonus. The present report investigated the role of high dose piracetam in patients with cerebellar ataxia. Methods: Eight patients with autosomal dominant cerebellar ataxia were given intravenous piracetam 60 g/day by a structured protocol for 14 days. The baseline and end-of-the study evaluations were based on the International Cooperative Ataxia Rating Scale. Results: Statistical analysis demonstrated a significant improvement in the patients' total score (P = 0.018) and a subscale analysis showed statistical significance for only the posture and gait disturbances item (P = 0.018). Conclusion: This study is providing good clinical observation in favour of high dose piracetam infusion to reduce the disability of the patients by improving their gait ataxia.
dc.identifier.doi10.1111/j.1365-2710.2008.00901.x
dc.identifier.issn0269-4727
dc.identifier.pubmed18315783
dc.identifier.urihttps://hdl.handle.net/11424/228865
dc.identifier.wosWOS:000253710500011
dc.language.isoeng
dc.publisherBLACKWELL PUBLISHING
dc.relation.ispartofJOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectataxia
dc.subjectautosomal dominant
dc.subjectcerebellar
dc.subjectpiracetam
dc.subjecttreatment
dc.subjectSPINOCEREBELLAR ATAXIA
dc.titleThe effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients
dc.typearticle
dspace.entity.typePublication
local.avesis.idf46d7ffc-efbd-4424-b652-b1c2ecc5f78c
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages4
oaire.citation.endPage178
oaire.citation.issue2
oaire.citation.startPage175
oaire.citation.titleJOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
oaire.citation.volume33
relation.isAuthorOfPublication2cdba045-abf1-46b3-ba7f-6b06308d9e57
relation.isAuthorOfPublication.latestForDiscovery2cdba045-abf1-46b3-ba7f-6b06308d9e57

Files

Collections

Research Outputs